(MM) (PCYC) 銘柄情報

Actually that distinction will belong to IPIX...

"watch CBMG this could be the next PCYC" - Exodus

Good I found this one!

watch CBMG this could be the next PCYC

HUGE CONGRAT$$$$ TO ALL LONGS!!!

http://www.finviz.com/quote.ashx?t=PCYC&ty=c&ta=1&p=d

$82 52WL= WOW

Like a Texas Holdem Tournament. What will J&J DO?

Thinking J&J counters? Got plenty of time for the deal to close.

It ain't over until it's over > "PCYC has traded higher the last couple weeks behind rumors that JNJ is nearing a deal to acquire the company.
Instead, AbbVie announced it was buying PCYC for $21 billion, at least $3 billion higher than JNJ's bid.
While this may seem like a closed book, PCYC investors should hold out a little bit longer, as counter bids might very well follow.
AbbVie (NYSE:ABBV) has beaten Johnson & Johnson (NYSE:JNJ) to the punch, outbidding to acquire Pharmacyclics (NASDAQ:PCYC) for $21 billion. Given the speculation that surrounded the acquisition of Pharmacyclics, this outcome is a big shock, as investors almost universally thought Johnson & Johnson was nearing a deal. Therefore, with AbbVie stating that it is the one to acquire Pharmacyclics, it appears like a done deal, that Pharmacyclics and its drug Imbruvica will belong to AbbVie. However, I wouldn't close this book just yet."

$261 a share

AbbVie to Buy Pharmacyclics in $21 Billion Deal -- 2nd Update

Source: Dow Jones News
By Jonathan D. Rockoff and Peter Loftus
AbbVie Inc. said late Wednesday it will buy cancer biotech Pharmacyclics Inc. in a $21 billion deal that returns the North Chicago, Ill., drug company to deal-making after backing away from a big tax-lowering takeover last year.

The deal, a mix of cash and stock for $261.25 a share, would give AbbVie a presence in the multibillion-dollar blood-cancer market, and lessen its reliance on an aging rheumatoid-arthritis drug that accounts for most of its sales.

AbbVie had reached a $54 billion agreement to buy Irish drug company Shire PLC last year, before abruptly walking away after the Obama administration took steps to deter such tax-lowering deals.

AbbVie said it expects the deal to close in the middle of this year.

Pharmacyclics, of Sunnyvale, Calif., sells a drug called Imbruvica with partner Johnson & Johnson. Imbruvica has been approved for two blood cancers--a rare lymphoma and a form of leukemia. In January, the Food and Drug Administration greenlighted Imbruvica's use for a rare form of cancer affecting the immune system.

In its first full year on sale, the pill had $548 million in world-wide net product revenue last year, Pharmacyclics reported. The company projects sales will reach $1 billion this year.

Some analysts, citing Imbruvica's impressive performance in clinical trials, estimate sales could peak at $5 billion a year.

AbbVie will be counting on such high sales. Pharmacyclics shares began the year at $124.46, before rising on reports in recent weeks that the company was up for sale.

The deal also would give AbbVie an experienced sales force for marketing to doctors who treat blood cancers, which would be especially helpful if AbbVie's own blood-cancer drug in development makes it to market.

AbbVie has a partnership with Roche Holding AG to co-develop venetoclax, or ABT-199, for patients with chronic lymphocytic leukemia. AbbVie may file for regulatory approval of the drug later this year, pending results from a clinical trial.

AbbVie has been looking to branch out beyond its reliance on rheumatoid-arthritis therapy Humira. It is AbbVie's biggest-selling product, notching $12.5 billion in sales in 2014, more than 60% of the company's total revenue. But a key U.S. patent for the drug expires in late 2016, and equivalent patents expire in the majority of European countries in 2018. The patent expirations could trigger the introduction of competing, "biosimilar" copies of Humira, eroding sales of the brand.

But some analysts question whether Imbruvica can reach the lofty sales targets, unless it can prove effective against other kinds of tumor types and perhaps different diseases--a big risk.

Another issue for AbbVie will be sharing Imbruvica with a rival drug company. J&J helps sell Imbruvica and splits the profits from the drug under the terms of a 2011 deal with Pharmacyclics.

For Pharmacyclics, a takeover would culminate a topsy-turvy history. It bought the molecule that became Imbruvica during a fire sale by gene-sequencing company Celera Genomics in 2006.

J&J said in a statement that the deal confirms the potential it saw in Imbruvica and the company is "looking forward to continuing our collaboration with the team at AbbVie."

Write to Jonathan D. Rockoff at jonathan.rockoff@wsj.com and Peter Loftus at peter.loftus@wsj.com

Into the stratosphere...yay!

PCYC D

Ballin out!!

Roth Capital Maintains Buy On Pharmacyclics Following Waldenstrom’s EMA Submission Acceptance http://www.smarteranalyst.com/2014/12/01/roth-capital-maintains-buy-on-pharmacyclics-following-waldenstroms-ema-submission-acceptance/

$PCYC DD Notes ~ http://www.ddnotesmaker.com/PCYC

bullish very long term

$PCYC recent news/filings

## source: finance.yahoo.com

Tue, 28 Oct 2014 22:27:30 GMT ~ Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results

[at noodls] - SUNNYVALE, Calif., Oct. 28, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it will hold a conference call and audio webcast to discuss its financial results for the third ...

read full: http://www.noodls.com/view/346B96EC29F7E11FBBE7F6B4AF572C356E1F38D6
*********************************************************

Wed, 22 Oct 2014 17:40:03 GMT ~ Pharmacyclics Up on Label Expansion Efforts for Imbruvica


read full: http://finance.yahoo.com/news/pharmacyclics-label-expansion-efforts-imbruvica-174003373.html
*********************************************************

Mon, 20 Oct 2014 12:53:47 GMT ~ PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/141020/pcyc8-k.html
*********************************************************

Mon, 20 Oct 2014 12:13:47 GMT ~ Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia

[at noodls] - SUNNYVALE, Calif., Oct. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration ...

read full: http://www.noodls.com/view/AC3F7A83039CCE6D66CB11480FC277CC2FACC79E
*********************************************************

Mon, 20 Oct 2014 12:00:00 GMT ~ Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia

[PR Newswire] - SUNNYVALE, Calif., Oct. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration ...

read full: http://finance.yahoo.com/news/pharmacyclics-files-supplemental-drug-application-120000771.html
*********************************************************


$PCYC charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$PCYC company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/PCYC/company-info
Ticker: $PCYC
OTC Market Place: Not Available
CIK code: 0000949699
Company name: Pharmacyclics, Inc.
Incorporated In: DE, USA


$PCYC share structure

## source: otcmarkets.com

Market Value: $9,849,069,817 a/o Oct 28, 2014
Shares Outstanding: 75,269,926 a/o Jul 29, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0001
$PCYC extra dd links

Company name: Pharmacyclics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PCYC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PCYC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PCYC+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PCYC/news - http://finance.yahoo.com/q/h?s=PCYC+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PCYC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PCYC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PCYC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PCYC
DTCC (dtcc.com): http://search2.dtcc.com/?q=Pharmacyclics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Pharmacyclics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Pharmacyclics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PCYC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000949699&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PCYC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PCYC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PCYC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PCYC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PCYC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PCYC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PCYC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PCYC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PCYC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PCYC+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PCYC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PCYC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PCYC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PCYC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PCYC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PCYC/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PCYC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PCYC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PCYC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PCYC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PCYC



$PCYC DD Notes ~ http://www.ddnotesmaker.com/PCYC

We Believe Pharmacyclics Shares Are Positioned For Growth, Says Roth Capital http://www.smarteranalyst.com/2014/08/01/we-believe-pharmacyclics-shares-are-positioned-for-growth-says-roth-capital/

$PCYC Roth Capital Reiterates Buy On Pharmacyclics In Light Of Recent FDA Approval For Imbruvica http://www.smarteranalyst.com/2014/07/29/roth-capital-reiterates-buy-on-pharmacyclics-in-light-of-recent-fda-approval-for-imbruvica/

Wedbush Reiterates Outperform On Pharmacyclics As CHMP Recommends EU Approval Of Imbruvica http://www.smarteranalyst.com/2014/07/25/wedbush-reiterates-outperform-on-pharmacyclics-as-chmp-recommends-eu-approval-of-imbruvica/

Most interesting post, FULL of uncertainties, opinion, rumor, hearsay...all "eloquently" gelled to give the APPEARANCE of knowledgeable "facts" and learned "prophesy".
Nice TRY tho--ENJOY your shorting--I WILL take your money.
GO PCYC

Regardless of anything, this is a steal at these prices. Massive overselling and RSI at 19.!.!.!

Breaking!!!
Check this out:
The Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib...

http://bit.ly/1cwXHZ1

Big dump on this turd stock

This guy only posted ONCE and has vanished. Wonder how his short is going...

Great post
Your subject matter reminds me of comments made at times, on the PPHM board. Your comments give much room for thought before investing in ANY company especially pharma.

Thks for info

cc transcript

http://www.earningsimpact.com/Transcript/84398/PCYC/Pharmacyclics%2c-Inc----Q3-2013-Earnings-Call

Interesting perspective.

Have you seen ctix with kevetrin. I like your reasons for shorting pcyc looks like you may know lots about pcyc good luck

I did well going long on PCYC and now that ibrutinib is in the hands I am shorting PCYC and banking much of my portfolio on this move. PCYC is a hot favorite among investors, but as an experienced and recently retired executive from the pharmaceutical industry I have seen wonder companies rise and flame out again and again.

In this case my explorations among thousands of industry contracts steers me toward being disappointed in the prospects for PCYC. There is no doubt ibrutinib is a wonder drug and perhaps the great discover in this space in the history of hematology/oncology products. It would be successful, perhaps the next blockbuster, if PCYC management had any pharmaceutical industry experience whatsoever. They do not. As a result investors are going to be sorely disappointed if and when the FDA decides the drug's future.

In my 30 years of leadership in the pharmaceutical industry I have seen many small biopharma companies come and go. In many cases the value of the science had little to do with the company's failure. In all cases the failure was do to poor management. Among those failures the majority were a result of a biopharma company having management experience in this extremely heavily regulated industry. This lack of industry experience is what will lead to disappointment among PCYC investors.

I have heard that the proximate cause of disappointment will be a result of the inexperience and lack of cultural understanding on the part of PCYC's COO. I understand she follows a 1950's management style, rewarding sycophants while punishing messengers who bring her bad news. Unfortunately, in this highly regulated industry it is foolish, if not corporately fatal, to ignore bad news. A positive attitude will absolutely not change the outcome of a clinical trial. Devoting massive financial resources will not accelerate a clinical trial. The COO knows corporate politics and is devoted to an imaginary management style but neither of those characteristics is a positive in the world of drug development.

One of the key attributes I review when analyzing a company is the turnover of the CMO. PCYC pad over $10 million to fire a CMO having one of the best FDA approval records in the industry. My opinion is that she offered advice based on a lifetime of experience which was rejected by the CEO and COO. In their fantasy world the CMO did not share their vision of a broad initial approval. So they fired her. I theorize that she told them to target smaller indications where they had the highest chances of approval. I also theorize PCYC management didn't want to hear that because they wanted to "play to win." Because they are inexperienced. Inexperience thrives on sycophants and PCYC loves sycophants; politics replace experience and politics lead to failure.

Many beginner and inexperienced biopharma senior executives think they will succeed because, "unlike other biopharma companies, we are playing to win. We're not playing not to lose." That is flawed logic and has proven fatal to innumerable biopharma companies run by inexperienced management. Yes, you might be able to make a billion dollars in a previous venture selling widgets, but without biopharma industry experience you are highly unlikely to succeed in a biopharma venture. Incompetent management has a better chance of making a mediocre drug successful than PCYC's inexperienced management has of making a potential wonder drug successful.

That is why PCYC will disappoint and that is why I am shorting it.

Ctix will make Pcyc move 2014 cancer treatment for multiple types by activating p53 and two other drugs a antibiotic and a psiarisis drug both phase 2 .

PCYC- Thank You Cramer for your piece on PCYC this evening on " Speculation Friday " this is one of my babies since late 2011. Mentioned the word "speculative" a few times too many times to cover your ugly ass as always. We all know every stock is speculative. Thanks though. Be Long and Prosper. + 125% 2013 PCYC

6:31AM Pharmacyclics announces NDA filing for ibrutinib accepted in two B-cell malignancies by the FDA; triggers a $75 mln milestone payment to the co (PCYC) 111.70 : Co announced that the FDA has accepted for filing its New Drug Application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia /small lymphocytic lymphoma. On June 28, 2013 Pharmacyclics submitted a NDA under section 505(b) of the Food, Drug & Cosmetic Act for ibrutinib. On Aug 27, 2013 the FDA notified Pharmacyclics that they have completed their filing review and determined that the application is sufficiently complete to permit a substantive review. The FDA's acceptance of the NDA triggers a $75 mln milestone payment to Pharmacyclics under its Collaboration Agreement with Janssen Biotech, a subsidiary of Johnson & Johnson (JNJ)

I hear ya - what's the next pick comin up.

I'm always hunting the next PO...just sayin...

Hey bux what's your take on high flier ..

Hope all is well my friend

Gix

GAAP net income for the quarter ended June 30, 2013 was 12.4 million

http://www.earningsimpact.com/Transcript/82556/PCYC/Q2-2013-Earnings-Call

This guy at mantlecell.blogspot.com/?m=1 claims that his mantle cell lymphoma has decreased by 88% after 63 days on Ibrutinib. Pretty cool!

You would think this thing would move back up. What the hell. I don't have all week. Don't pump

Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration

Apr 8, 2013 06:30:00 (ET)


SUNNYVALE, Calif., April 8, 2013 /PRNewswire via COMTEX/ -- Pharmacyclics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients with deletion of the short arm of chromosome 17 (deletion 17p). Patients harboring a deletion within chromosome 17 generally have poor response to chemoimmunotherapy and have limited treatment options. The presence of deletion 17p is one of the worst prognostic factors in patients with CLL.

In February 2013, FDA granted Breakthrough Therapy Designations for ibrutinib as a monotherapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and as a monotherapy for the treatment of patients with Waldenstrom's macroglobulinemia (WM), both of which are also B-cell malignancies. Ibrutinib is jointly being developed by Pharmacyclics and Janssen for treatment of B-cell malignancies.

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where "preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development." The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act. Pharmacyclics, together with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the FDA filing requirements for the use of ibrutinib in CLL patients with deletion 17p.

The FDA Breakthrough Therapy Designation for ibrutinib in CLL patients with deletion 17p was based on data from pre-clinical and clinical studies where ibrutinib as a monotherapy was used to treat patients with this disease. Ibrutinib has the potential to improve the outcome in this serious and life-threatening disease which has a poor prognosis. In addition, Pharmacyclics and Janssen have recently initiated a Phase II study of ibrutinib in patients with CLL deletion 17p, RESONATE(TM) -17, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior CLL treatment (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study opened this year and Pharmacyclics plans to enroll 111 patients worldwide.

About Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL) is a slow-growing blood cancer that starts in the white blood cells (lymphocytes), most commonly from B-cells. CLL is the second most common adult leukemia. Approximately 16,000 patients in the US are diagnosed each year with CLL. The prevalence of CLL is approximately 113,000 in the US. The disease is a chronic disease of the elderly with an average survival of about 5 years. Patients commonly receive multiple lines of treatment over the course of their disease.

In CLL the genetic mutation 17p deletion occurs when the short arm of chromosome 17 is missing. Del 17p is associated with abnormalities of a key tumor suppressor gene, TP53, which results in poor response to chemoimmunotherapy and worse treatment outcomes. It occurs in about 7% of treatment naive CLL patients and is estimated to be approximately 20% to 40% of relapsed or refractory patients harboring the mutation.

About Ibrutinib

Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel - regulation of apoptosis, adhesion, and cell migration and homing. Through these multiple signals, BTK regulation helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a micro environment necessary for survival.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date five Phase III trials have been initiated with ibrutinib and a total of 26 trials are currently registered on www.clinicaltrials.gov .

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com .

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

SOURCE Pharmacyclics, Inc.

http://rt.prnewswire.com/rt.gif?NewsItemId=SF90058&Transmission_Id=201304080630PR_NEWS_USPR_____SF90058&DateId=20130408

Pharmacyclics Gets New Breakthrough-Therapy Designation for Ibrutinib

By Saabira Chaudhuri

Pharmacyclics Inc. (PCYC) said the U.S. Food and Drug Administration granted an additional breakthrough-therapy designation for its investigational oral agent ibrutinib as a monotherapy to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with deletion of the short arm of chromosome 17.

The designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases when preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

Pharmacyclics noted patients harboring a deletion within chromosome 17 generally have poor response to chemoimmunotherapy and have limited treatment options.

Chronic lymphocytic leukemia is a slow-growing blood cancer that starts in the white blood cells. It is the second most common adult leukemia, and about 16,000 patients in the U.S. are diagnosed each year with this cancer, according to data cited by Pharmacyclics.

In February, the FDA granted breakthrough-therapy designations for ibrutinib as a monotherapy for the treatment of patients with relapsed or refractory mantle-cell lymphoma and as a monotherapy for the treatment of patients with Waldenstrom's macroglobulinemia, both of which are also B-cell malignancies.

Ibrutinib is being developed jointly by Pharmacyclics and Janssen Biotech Inc., a unit of Johnson & Johnson (JNJ), to treat B-cell malignancies.

Shares of Pharmacyclics closed Friday at $75.55 and were inactive in recent premarket trading. The stock has more than doubled in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

April 08, 2013 08:03 ET (12:03 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc. 040813 12:03 -- GMT Story ID: APR082013_DJB_010v Keywords: ALL COMPANY NEWS, NEW PRODUCTS & SERVICES, HEALTH CARE Symbols: JNJ, PCYC

8:19AM Pharmacyclics prices public offering of common stock at $94.20 (PCYC) 94.20 : Co announced the pricing of a previously announced underwritten registered public offering of 2,200,000 shares of its common stock, representing approximately 3.1% of the shares of common stock currently outstanding, at a public offering price of $94.20 per share. All of the shares are being sold by Pharmacyclics. The offering is expected to close on March 13, 2013, subject to customary closing conditions. J.P. Morgan Securities LLC is acting as sole manager for the offering

Any opinions as to what is an attractive entry point for this company?

7 Companies Fighting To Cure Cancer

http://seekingalpha.com/article/1073451-7-companies-fighting-to-cure-cancer

the boys are raking in the cash here

PCYC could get a boost above 55 and a gap fill

little gap to fill here

CURRENT PRICE 53.97, at resistance, 54.05 ± 1.73, type triple+, strength 10

RESISTANCE ABOVE +6.9% at 57.68 ± 1.85, type double, strength 6
+16.5% at 62.87 ± 2.01, type triple+, strength 10
+26.8% at 68.46 ± 2.19, type triple, strength 3

source: http://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=PCYC

http://beta.fool.com/insidermonkey/2012/11/21/billionaire-steve-cohen-bought-drug-manufacturer/17003/?ticker=PCYC&source=eogyholnk0000001

6:36AM Pharmacyclics misses by $0.01, beats on revs (PCYC) 57.37 : Reports Q1 (Sep) earnings of $1.14 per share, $0.01 worse than the Capital IQ Consensus Estimate of $1.15; revenues rose 256,650.0% year/year to $102.7 mln vs the $99.74 mln consensus. Revenue for the fiscal quarter ended September 30, 2012 consisted primarily of $100 mln of license and milestone revenue due to the co's achievement of two clinical milestones in connection with the co's collaboration and license agreement with Janssen Biotech. At September 30, 2012, the co had cash, cash equivalents and marketable securities of $286.1 mln, which compares with $203.6 mln at June 30, 2012. To date, the Company has received three milestone payments from Janssen of $50 mln each under the Agreement. The co may receive up to an additional $675 mln in development and regulatory milestone payments, however clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

6:32AM Pharmacyclics triggers another significant milestone payment for Phase III chronic lymphocytic leukemia combination trial (PCYC) 65.56 : Co announces that the international, randomized Phase III clinical trial of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a third $50 mln milestone payment obligation from Janssen Biotech, one of the Janssen Pharmaceutical Companies, worldwide collaborator on ibrutinib in oncology and sponsor of this CLL3001 trial.

I believe at ASH

when is the next data release here

is this just a level off or a correction